Cargando…
Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma
Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340133/ https://www.ncbi.nlm.nih.gov/pubmed/37456486 http://dx.doi.org/10.7759/cureus.40365 |
_version_ | 1785072005686493184 |
---|---|
author | Ibne Ali Jaffari, Syed Muhammad Hashmi, Masooma Hashmi, Abdul Wasey Nisar, Samaha Ashraf, Hafsa Tariq, Ghufran Farooq, Arslan Awan, Javeria Zaidi, Syed Muhammad Jawad Kaneez, Mehwish |
author_facet | Ibne Ali Jaffari, Syed Muhammad Hashmi, Masooma Hashmi, Abdul Wasey Nisar, Samaha Ashraf, Hafsa Tariq, Ghufran Farooq, Arslan Awan, Javeria Zaidi, Syed Muhammad Jawad Kaneez, Mehwish |
author_sort | Ibne Ali Jaffari, Syed Muhammad |
collection | PubMed |
description | Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan. Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children’s Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed. Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 ± 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management. |
format | Online Article Text |
id | pubmed-10340133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-103401332023-07-14 Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma Ibne Ali Jaffari, Syed Muhammad Hashmi, Masooma Hashmi, Abdul Wasey Nisar, Samaha Ashraf, Hafsa Tariq, Ghufran Farooq, Arslan Awan, Javeria Zaidi, Syed Muhammad Jawad Kaneez, Mehwish Cureus Pediatrics Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan. Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children’s Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed. Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 ± 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management. Cureus 2023-06-13 /pmc/articles/PMC10340133/ /pubmed/37456486 http://dx.doi.org/10.7759/cureus.40365 Text en Copyright © 2023, Ibne Ali Jaffari et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pediatrics Ibne Ali Jaffari, Syed Muhammad Hashmi, Masooma Hashmi, Abdul Wasey Nisar, Samaha Ashraf, Hafsa Tariq, Ghufran Farooq, Arslan Awan, Javeria Zaidi, Syed Muhammad Jawad Kaneez, Mehwish Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma |
title | Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma |
title_full | Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma |
title_fullStr | Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma |
title_full_unstemmed | Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma |
title_short | Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt’s Lymphoma |
title_sort | infection-associated mortality during induction chemotherapy in group b intermediate-risk pediatric burkitt’s lymphoma |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340133/ https://www.ncbi.nlm.nih.gov/pubmed/37456486 http://dx.doi.org/10.7759/cureus.40365 |
work_keys_str_mv | AT ibnealijaffarisyedmuhammad infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT hashmimasooma infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT hashmiabdulwasey infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT nisarsamaha infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT ashrafhafsa infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT tariqghufran infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT farooqarslan infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT awanjaveria infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT zaidisyedmuhammadjawad infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma AT kaneezmehwish infectionassociatedmortalityduringinductionchemotherapyingroupbintermediateriskpediatricburkittslymphoma |